https://www.selleckchem.com/pr....oducts/brefeldin-a.h
001). The main reason for discontinuation was disease activity without severe side effects on either treatment. Our findings support efficacy and tolerance of both drugs in early-treated treatment-naive MS patients, arguing in favour of efficient early immunomodulation in MS patients. Both drugs significantly reduced the incidence of new relapses and Gd-enhancing lesions on treatment with FTY being more frequently prescribed than DMF, especially in patients with evidence of higher clinical disease activity. Our findings support effi
Мне нравится
Комментарий
Перепост
